Nucleic Acids Research APC and Open Access: Current OUP Pricing, Agreements, and the Real Value Question

The current NAR author-guidelines page is explicit:

• NAR is fully open access
• accepted papers must pay the open-access charge or use an institutional agreement
• the current charge is $4,192
• the fee is exclusive of taxes
• corresponding authors at participating institutions may publish through a Read and Publish agreement
• corresponding authors in eligible low and middle income countries may receive a waiver or discount

That is a materially different answer from the older NAR APC figures still circulating online. If you still see ~$3,155 or "free for standard research articles," that is stale.

The current working number is $4,192, not the older lower fee.

On price alone, $4,192 is not trivial. But NAR is not being evaluated as a generic OA journal. It sits in a very specific position:

• top-tier molecular biology and genomics visibility
• strong long-window citation behavior
• very high total citation count
• unusual authority in tools, databases, RNA biology, and nucleic-acid methods

That matters because a NAR paper is often being chosen for durable utility rather than journal glamour alone. A good database paper, web server paper, or highly reusable methods paper can justify the price differently than a one-off primary research article in another journal family.

Those are not decorative metrics. They explain why NAR can ask for a real APC and still remain a serious target for genomics, computational biology, RNA, and nucleic-acid research.

The year-over-year read matters here. NAR's JIF is flat at 13.1 from 2023 to 2024, after coming down from the pandemic-era peak. That makes the current price easier to read honestly: you are not paying for a temporary citation spike. You are paying for a journal with a stable upper-tier citation profile and very strong long-tail utility.

OUP's author guidance makes the institutional-coverage logic explicit.

The three most important payment paths are:

One operational point matters more than many authors realize: the corresponding author must list the qualifying institution correctly at submission to be eligible for Read and Publish coverage. OUP explicitly says you cannot change the corresponding author after submission just to unlock agreement funding.

That makes payment planning a submission-stage issue, not a post-acceptance cleanup task.

In our pre-submission review work, the NAR APC becomes worth paying only when the manuscript has the kind of durable field utility NAR readers actually keep citing.

Methods papers without real community utility get overestimated. The journal's numbers are strong because NAR publishes work researchers return to repeatedly. If a method is technically interesting but unlikely to be widely reused, the APC is much harder to justify.

Database and web-server logic gets treated casually. Authors often assume the journal will forgive maintenance, usability, or benchmarking gaps because the field knows the topic is important. In practice, NAR is one of the least forgiving places for half-built community resources.

Teams compare NAR only on impact factor and ignore article identity. A NAR methods paper, a database issue paper, and a regular biology paper do not behave the same way after publication. The fee makes most sense when the article identity matches the journal's long-tail utility pattern.

That is why the APC question is really a manuscript-identity question.

The APC is easier to justify when:

• the paper is clearly a NAR paper rather than a generic molecular biology submission
• the work has reusable value, durable utility, or infrastructure significance
• Read and Publish coverage or grant funding is available
• the authors want the discoverability and open-access reach that fully OA publication brings

The APC is harder to justify when:

• the manuscript is a narrower paper that would fit a lower-cost journal equally well
• the work is interesting but not clearly reusable or reference-worthy
• the bill would come from personal funds
• the article identity is fuzzy enough that the journal fit is still uncertain

The current official NAR APC is $4,192. That is the number authors should use in 2026 unless they already know they have agreement coverage or eligibility for a waiver or discount.

The stronger practical answer, though, is:

• there is no free subscription route
• many authors pay less or nothing through institutional coverage
• the fee is easiest to justify when the paper has the kind of durable reuse value that NAR actually rewards

If you want to decide whether the manuscript is truly strong enough and correctly positioned for NAR before worrying about the invoice, a Nucleic Acids Research submission readiness check is the best next move.